Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: A Children's Oncology Group Study

I. Ming Chen, Richard C. Harvey, Charles G. Mullighan, Julie Gastier-Foster, Walker Wharton, Huining Kang, Michael J. Borowitz, Bruce M. Camitta, Andrew J. Carroll, Meenakshi Devidas, D. Jeanette Pullen, Debbie Payne-Turner, Sarah K. Tasian, Shalini Reshmi, Catherine E. Cottrell, Gregory H. Reaman, W. Paul Bowman, William L. Carroll, Mignon L. Loh, Naomi J. WinickStephen P. Hunger, Cheryl L. Willman

Research output: Contribution to journalArticle

157 Scopus citations

Abstract

As controversy exists regarding the prognostic significance of genomic rearrangements of CRLF2 in pediatric B-precursor acute lymphoblastic leukemia (ALL) classified as standard/intermediate-risk (SR) or high-risk (HR), we assessed the prognostic significance of CRLF2 mRNA expression, CRLF2 genomic lesions (IGH@-CRLF2, P2RY8-CRLF2, CRLF2 F232C), deletion/mutation in genes frequently associated with high CRLF2 expression (IKZF1, JAK, IL7R), and minimal residual disease (MRD) in 1061 pediatric ALL patients (499 HR and 562 SR) on COG Trials P9905/P9906. Whereas very high CRLF2 expression was found in 17.5% of cases, only 51.4% of high CRLF2 expressors had CRLF2 genomic lesions. The mechanism underlying elevated CRLF2 expression in cases lacking known genomic lesions remains to be determined. All CRLF2 genomic lesions and virtually all JAK mutations were found in high CRLF2 expressors, whereas IKZF1 deletions/mutations were distributed across the full cohort. In multivariate analyses, NCI risk group, MRD, high CRLF2 expression, and IKZF1 lesions were associated with relapse-free survival. Within HRALL, only MRD and CRLF2 expression predicted a poorer relapse-free survival; no difference was seen between cases with or without CRLF2 genomic lesions. Thus, high CRLF2 expression is associated with a very poor outcome in high-risk, but not standard-risk, ALL. This study is registered at www.clinicaltrials.gov as NCT00005596 and NCT00005603.

Original languageEnglish (US)
Pages (from-to)3512-3522
Number of pages11
JournalBlood
Volume119
Issue number15
DOIs
StatePublished - Apr 12 2012

    Fingerprint

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Chen, I. M., Harvey, R. C., Mullighan, C. G., Gastier-Foster, J., Wharton, W., Kang, H., Borowitz, M. J., Camitta, B. M., Carroll, A. J., Devidas, M., Pullen, D. J., Payne-Turner, D., Tasian, S. K., Reshmi, S., Cottrell, C. E., Reaman, G. H., Bowman, W. P., Carroll, W. L., Loh, M. L., ... Willman, C. L. (2012). Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: A Children's Oncology Group Study. Blood, 119(15), 3512-3522. https://doi.org/10.1182/blood-2011-11-394221